Peloton Interactive Inc

Peloton is betting on a new lineup of treadmills, including the Foldable Peloton Tread Flex, the Peloton Tread Vision and the Peloton Tread+ Vision priced at $6,695, to reverse a long streak of failed product launches. The stock is down 20% this year and 95% over the last five years. In the most recent quarter, revenue was flat at $607 million compared with the same period a year ago, while net income rose from $22 million to $62 million. The company's core business model remains deeply challenged, with cheaper gym memberships and competing products undercutting its pricing. The stock is down 8% in the last month.

Morgan Stanley downgraded Peloton to Underweight from Equal Weight on Tuesday, warning that a shift toward strength training and gyms will pressure the connected fitness company's subscriber base. Analyst Nathan Feather cut his price target to $4.50 from $5.00, implying about 16% downside, and lowered fiscal 2027 and 2028 estimates, now sitting 2% and 9% below consensus on fiscal 2028 revenue and EBITDA, respectively. Feather noted gross additions are down about 78% from their peak and connected fitness subscriber growth fell 9% year over year in fiscal 2026, citing structural headwinds such as Google search interest in strength training growing at an 8% compound annual rate and overtaking cardio, while gym membership rose to 24% from 20% in 2021. He argued consensus forecasts are too bullish, modeling a return to roughly flat subscriber growth within three years, and wrote that "cheap is not a catalyst," expecting a sub-$2,000 treadmill launch before the holidays to be only incremental.

Roivant Sciences shares rallied 24% after the pharma company reported positive Phase 2 trial results for its subsidiary Pulmovant's mosliciguat, which showed a clinically meaningful and statistically significant reduction in pulmonary vascular resistance in patients with pulmonary hypertension and interstitial lung disease. Meanwhile, Lockheed Martin edged up 0.7% after UBS upgraded the stock to buy, citing underappreciated earnings growth potential. Novartis tumbled 12% after its del-desiran drug failed to show significant improvement in a Phase 3 trial for myotonic dystrophy type 1. Peloton Interactive slid more than 4% following a Morgan Stanley downgrade to underweight, citing structural headwinds in fitness. Boston Scientific slipped over 2% after warning that a recent cyberattack likely impacted its 2026 sales and profit targets. Bloom Energy rose over 6% as it prepares to join the S&P 500 on Sept. 21, having gained about 190% this year on the AI data center buildout.

Peloton's second quarter results were met with a negative market reaction as flat revenue growth and a decline in connected fitness subscribers weighed on sentiment. Revenue was $607.7 million versus analyst estimates of $595.7 million, adjusted EPS was $0.13 versus $0.11, and adjusted EBITDA was $142.3 million versus $150.5 million. Management attributed the mixed performance to operational improvements and strategic investments in new product categories, while also acknowledging the impact of involuntary churn following an algorithm change. CEO Peter Stern emphasized material improvements in the financial and operational foundation, citing advancements in product innovation and cost structure. During the earnings call, analysts pressed on new product introductions, revenue contributions, churn normalization, Peloton IQ engagement, and hardware go-to-market priorities.

Peloton Interactive reported its first full year of profitability with fiscal 2026 net income of US$63.2 million on revenue of US$2.45 billion, but issued fiscal 2027 revenue guidance of US$2.30 billion to US$2.40 billion, implying a year-over-year decline. The company also filed a US$171.60 million shelf registration for Class A stock tied to employee stock ownership plans. The guidance reinforces ongoing pressure on hardware sales and connected fitness subscriptions, even as Peloton shifts focus toward profitability and a subscription-centric model.

Several stocks made significant premarket moves following earnings reports and guidance updates. Peloton Interactive sank nearly 14% after reporting a year-over-year decline in active paying subscribers of 8.8%, despite revenue topping expectations. Moderna rose 4% after the FDA approved its mRNA flu vaccine, mFlusiva, for adults 50 and older. Versant Media jumped 5% after raising its full-year outlook and beating top and bottom lines, now expecting 2026 revenue of $6.2 billion to $6.45 billion and adjusted EBITDA of $1.9 billion to $2.05 billion. Warby Parker shed 7% after second-quarter revenue of $235.5 million missed the LSEG consensus estimate of $238 million, though EBITDA topped expectations and full-year guidance was reaffirmed. IonQ rose 3.9% on better-than-expected second-quarter revenue and full-year revenue guidance of $280 million to $290 million, exceeding the FactSet consensus of $268.6 million. Sandisk slid 10% as first-quarter revenue guidance of $10.3 billion to $10.8 billion appeared to disappoint traders, with the LSEG consensus at $10.47 billion, despite fourth-quarter beats. Figma shed 14% after full-year adjusted operating income guidance of $125 million to $135 million came in soft versus the FactSet consensus of $133.2 million. DoorDash added 4% after quarterly revenue of $4.45 billion beat the LSEG consensus of $4.34 billion. Zillow slid more than 11% after expanding CFO Jeremy Hofmann's role to include COO, while also reporting adjusted EPS of 52 cents beating estimates of 45 cents and revenue of $772 million beating estimates of $758 million, a day after announcing about 500 layoffs. Western Digital slumped more than 15% as current-quarter projections underwhelmed, calling for adjusted earnings of $4 a share on revenue of $4.1 billion, versus consensus of $3.81 a share on $4.04 billion. Salesforce fell almost 5% after naming Miguel Milano as operating chief. Duolingo tumbled 7% after current-quarter revenue guidance of $302 million missed the FactSet consensus of $303.9 million. Bumble fell 5% after posting a second-quarter loss of 84 cents per share versus an expected profit of 25 cents, and issuing third-quarter adjusted EBITDA guidance of $56 million to $60 million below the $68.7 million consensus. AppLovin tanked nearly 20% after third-quarter adjusted EBITDA guidance of $1.71 billion to $1.74 billion missed the StreetAccount consensus of $1.75 billion.

We are highlighting three consumer discretionary stocks that we consider risky: Peloton, Pool, and Planet Fitness. Peloton has seen its earnings per share decline by 22.3% annually over the past five years, and its free cash flow margin is expected to drop by 3.6 percentage points in the coming year. Pool's revenue growth of 4.4% annually over the last five years lagged peers, and its free cash flow margin of 7.5% limits investment capacity. Planet Fitness faces shrinking same-store sales and a forecasted 6.6 percentage point decline in free cash flow margin, indicating rising capital needs.

Health tech analyst Stephanie Davis says wearable technology companies can learn from FitBit's past, noting that FitBit faced replacement cycle issues and intense competition after going public, similar to companies like Roomba, Peloton, and GoPro. Davis argues that a hardware-plus-subscription model is more sustainable but warns that pricing subscriptions too high can create user friction. She describes current AI features in wearables as largely a party trick, suggesting the real opportunity lies in targeting users with chronic conditions rather than already healthy individuals. Davis also notes that smaller independent wearable companies struggle to compete against tech giants like Apple and Google, which can integrate devices into broader ecosystems.